Kristīne Jučkoviča has been appointed as strategic and health policy director of AS AB City, the parent company of AS Repharm group and drug manufacturer AS Olainfarm.
K. Jučkoviča will be responsible for the direction of uniform processes in the relations of the company group with external partners – state institutions, municipalities and non-governmental organizations. She will also be in charge of strengthening the reputation of the company group.
Also, Juchkoviča will be the spokesperson for the group of companies in explaining and expressing important strategic issues publicly in the media, in the Saeima and its commissions, in the Cabinet of Ministers, in ministries and elsewhere.
At the same time, Jučkoviča will continue her work as the executive director of the Latvian Pharmaceutical Care Association.
“AB City” board member Roberts Tavievs states that supplementing the management team is the next step in the implementation of the “Fit for 2025” strategy, which will optimize the management of the company group, bringing it even closer to the principles of rational, productive and efficient company operation.
The turnover of “AB City” concern in 2021 was 384.725 million euros, while the profit was 63.555 million euros. Financial data for 2022 have not yet been made public.
The holding company “AB City” is the parent company of “Repharm” and “Olainfarm”, the group also includes the owner of the “Mēness aptieku” network AS “Sentor farm aptiekas”, the wholesaler of medicinal products AS “Recipe Plus”, the manufacturer of herbal medicinal products AS “Rīgas farmaceitika fabrika” , a network of ambulatory care facilities AS “Veselības centru apviėna” and SIA “Centrala laboratorija”.
The company was registered in 2018, and its share capital is 126,536,960 euros. According to the information published on the company’s website, the real beneficiaries of “AB City” at the beginning of this year were Josif Apts, Sergejs Korniienko, Andrejs Leibovičs, Aleksandrs Livšits, Mihails Lurie, Jelena Nikitina, Jānis Oskerko and Roberts Tavievs. However, in August 2023, the company informed that changes had been made in the composition of the shareholders of “AB City”, including Apts leaving his job on the board of “Repharm”.
Source: LETA
2023-09-11 13:35:43
#Jučkoviča #appointed #strategic #health #policy #director #City
